SCHEMBL30003542

SCHEMBL30003542

Cc1cc(C(=O)CCc2nc(-c3ccc(Cl)cc3O)oc2C(C)C)ccc1OC(C)(C)CO

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARD Q03181 7/20 0.45
PPARA Q07869 7/20 0.45
PPARG P37231 6/20 0.45
S1PR1 P21453 2/20 0.32
S1PR3 Q99500 2/20 0.32
S1PR5 Q9H228 2/20 0.32
PDE4B Q07343 2/20 0.31
PDE11A Q9HCR9 2/20 0.31
MAPT P10636 2/20 0.30
KDM4E B2RXH2 1/20 0.30
LMNA P02545 1/20 0.30
KCNH2 Q12809 1/20 0.30
TSHR P16473 2/20 0.30
NPC1 O15118 1/20 0.30
POLB P06746 1/20 0.30
RAB9A P51151 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
HSD17B10 Q99714 1/20 0.30
HTR2A P28223 1/20 0.30
HTR2C P28335 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24742470 1.00 PPARD (0.45) PPARDPPARAPPARGS1PR1S1PR3
SCHEMBL30003512 0.93 PPARA (0.52) PPARDPPARAPPARGS1PR1S1PR3
SCHEMBL24658334 0.93 PPARA (0.52) PPARDPPARAPPARGS1PR1S1PR3
SCHEMBL20815372 0.93 PPARD (0.47) PPARDPPARAPPARGS1PR1S1PR3
SCHEMBL2466184 0.90 PPARD (0.52) PPARDPPARAPPARG
SCHEMBL12732406 0.90 PPARD (0.45) PPARDPPARAPPARGS1PR1S1PR3
SCHEMBL1765866 0.89 PPARA (0.45) PPARDPPARAPPARGS1PR1S1PR3
SCHEMBL24742577 0.88 PPARA (0.51) PPARDPPARAPPARGS1PR1S1PR3
SCHEMBL30003775 0.88 PPARA (0.51) PPARDPPARAPPARGS1PR1S1PR3
SCHEMBL2460886 0.88 PPARA (0.43) PPARDPPARAPPARGS1PR1S1PR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250333379-A1 Compounds Useful for Treating Liver Diseases ABIONYX PHARMA SA (FR) 2025-10-30 US disclosed
US-12297168-B2 Compounds useful for treating liver diseases ABIONYX PHARMA SA (FR) 2025-05-13 US disclosed
US-20240199575-A1 COMPOUNDS USEFUL FOR TREATING LIVER DISEASES ABIONYX PHARMA SA (FR) 2024-06-20 US disclosed
US-20230278952-A1 Compounds Useful for Treating Liver Diseases ABIONYX PHARMA SA (FR) 2023-09-07 US disclosed
US-11634387-B2 Compounds useful for treating liver diseases ABIONYX PHARMA SA (FR) 2023-04-25 US disclosed
US-20220363632-A1 Compounds Useful for Treating Liver Diseases ABIONYX PHARMA SA (FR) 2022-11-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230278952-A1 Compounds Useful for Treating Liver Diseases SLC10A1, FABP1, CPT1A PPARD 332/4885PPARA 94/4885PPARG 71/4885
US-20240199575-A1 COMPOUNDS USEFUL FOR TREATING LIVER DISEASES SLC10A1, FABP1, CPT1A PPARD 332/4885PPARA 94/4885PPARG 71/4885
US-11634387-B2 Compounds useful for treating liver diseases SLC10A1, FABP1, CPT1A PPARD 332/4885PPARA 94/4885PPARG 71/4885
US-20250333379-A1 Compounds Useful for Treating Liver Diseases SLC10A1, FABP1, CPT1A PPARD 332/4885PPARA 94/4885PPARG 71/4885
US-12297168-B2 Compounds useful for treating liver diseases SLC10A1, FABP1, CPT1A PPARD 332/4885PPARA 94/4885PPARG 71/4885
US-20220363632-A1 Compounds Useful for Treating Liver Diseases SLC10A1, FABP1, CPT1A PPARD 332/4885PPARA 94/4885PPARG 71/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.